Profile Technologies (PRTK) Misses Q2 EPS by 20c

Profile Technologies (NASDAQ: PRTK) reported Q2 EPS of ($0.96), $0.20 worse than the analyst estimate of ($0.76).

"We have made considerable progress during the past quarter in advancing our clinical development program for omadacycline, a therapy that we believe represents a significant opportunity for patients and for our shareholders," said Michael Bigham, Chairman and Chief Executive Officer, Paratek. "Additionally, we have extended our cash runway with the completion of a successful follow-on common stock offering in May, and have added further depth to our experienced leadership team. Going into the second half of 2015, we believe we are well positioned to execute on our future objectives."

For earnings history and earnings-related data on Profile Technologies (PRTK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Movano (MOVE) Misses Q2 EPS by 195c